April 24, 2018 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC:ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive CBD innovator specializing in the development of pharmaceutical and wellness products, and Level Brands Inc. (NYSE American: LEVB), an innovative marketing and licensing company that provides bold, unconventional, and socially responsible branding for leading businesses announced today the launch of their newest jointly developed cannabidiol (CBD) products. The products are CBD pain-relieving cream, marketed under LEVB subsidiary Ireland Men One (I’M1); CBD oral sprays marketed under BeTrū | kathy ireland® Health & Wellness; and CBD edibles, marketed under Chef Andre Carthen Edibles. The new products will be available in early Summer 2018 at in-store and online retailers nationwide. According to The Hemp Business Journal (as reported by forbes.com), the CBD market will grow to $2.1 billion by 2020.
In January 2018, Level Brands and Isodiol signed a license agreement, to work together to develop consumer products for kathy ireland® Health & Wellness, a licensor to Level Brands; products under the Chef Andre Carthen and Nicholas Walker brands, also licensors to Level Brands; as well as products for Level Brands subsidiary I’M1, the company’s lifestyle brand for millennial men.
“Our collaboration with Level Brands is taking a big step forward today,” said Marcos Agramont, CEO of Isodiol. “When we established this partnership, we envisioned bringing a variety of consistent, highly bioactive CBD products to the market and today is just the early stages of this process. Through Kathy’s large network and consumer base, not only are we able to target a variety of new mainstream channels, but we are also able to further achieve our goal of helping people around the globe understand how CBD is beneficial for the human body.”
“When we announced the extension of our license agreement with Isodiol this past January, we said that our vision is that Isodiol will become the leading CBD company in the world,” says Kathy Ireland, Level Brands’ Chairman Emeritus and Chief Brand Strategist. “The products we’re launching, take us in that direction in a powerful way. We continue to believe, based on our exhaustive research and decades of brand building, that the CBD industry will see enormous growth over the next decade on a global scale. Hemp has many natural and important uses that are beneficial in countless ways. It is important for people to remember that hemp, without THC, is similar to a grape without fermentation. It has no undesired psychological side effects. The Level Brands and Isodiol collaboration is bringing, and will continue to bring to market, the best quality hemp-derived CBD products, without any psychotropic elements.”
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
“Marcos Agramont” CEO & Director
COMPANY MEDIA :
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.